Posted on October 2nd, 2009 by
Among patients with advanced neuroendocrine tumors of the midgut, treatment with Sandostatin® LAR Depot (ocreotide acetate for injectable suspension) appears to significantly delay cancer progression. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.
Neuroendocrine tumors form from cells that release hormones in response to a signal from the nervous system. These tumors include carcinoid tumors, islet cell tumors, medullary thyroid carcinomas, pheochromocytomas, and Merkel cell carcinomas. Although they can occur in many different parts of the body, neuroendocrine tumors often develop in the digestive system.
Sandostatin LAR is a drug used to treat diarrhea and flushing associated with advanced carcinoid tumors and watery diarrhea associated with VIP (vasoactive intestinal polypeptide)–secreting tumors.
To evaluate whether Sandostatin LAR has anticancer effects in patients with metastatic neuroendocrine tumors of the midgut, researchers conducted a Phase IIIb study known as PROMID (Placebo-controlled, double-blind, prospective Randomized study on the effect of Ocreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine MIDgut tumors).
The study, which was conducted in Germany, enrolled 85 patients who were treated with either Sandostatin LAR or placebo. All of the study participants had locally inoperable or metastatic neuroendocrine tumors with the primary tumor in the midgut.
The study included patients with functioning and nonfunctioning neuroendocrine tumors. Functioning tumors produce symptoms that are related to the oversecretion of hormones.
The results of this study suggest that Sandostatin LAR may delay progression of metastatic neuroendocrine tumors of the midgut.
Reference: Rinke A, Muller H-H, Schade-Brittinger C et al. Placebo-controlled, doubled-blind, prospective, randomized study on the effect of ocreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Journal of Clinical Oncology. 2009;27:4656-4663.
Copyright © 2010 CancerConsultants. All Rights Reserved.
Tags: UNM CC Features
You must be logged-in to the site to post a comment.